Diarrheal diseases kill over 2 million children annually, and the Institute for OneWorld Health aims to combat this with novel anti-secretory drugs. The $46 million grant will support the development of new treatments to complement traditional approaches.
The Institute for OneWorld Health has received a multimillion-dollar grant from the Gates Foundation to combat VL, a fatal disease transmitted by sand flies. The grant will support a long-term control program, including Phase 4 demonstration studies and clinical trials in children.
The Sapling Foundation grant will support OneWorld Health's efforts to develop new medicines for infectious diseases affecting the developing world. The Institute develops affordable treatments for diseases like visceral leishmaniasis, malaria, and diarrhea, with a focus on pre-clinical studies and clinical trials.
Leishmaniasis, a fatal disease affecting 1.5 million people worldwide, will be controlled through paromomycin with the goal of delivering treatment for under $10. The Institute for OneWorld Health aims to change generations of families devastated by VL.
The Institute for OneWorld Health has been awarded $7.3 million by the Skoll Foundation to develop new, affordable medicines for infectious diseases in developing countries. The award recognizes the organization's innovative business model and its commitment to creating lasting improvements in complex social problems.
OneWorld Health recognized as a Business Leader of the Scientific American 50 for its groundbreaking work on affordable medicines. The institute has made significant progress in developing treatments for deadly parasitic diseases, with preliminary positive results announced for visceral leishmaniasis.
OneWorld Health plans to launch a network of volunteer pharmaceutical scientists to develop treatments for diseases like visceral leishmaniasis, Chagas disease, and malaria. The initiative aims to harness the expertise of industry professionals to address global health disparities.
Victoria Hale, Institute for OneWorld Health leader, joins Leadership Foundation Fellows Program to develop skills and share insights with women leaders worldwide. She aims to leverage powerful connections and partnerships to drive institutional change.
Victoria Hale, founder of Institute for OneWorld Health, recognized by the Schwab Foundation for her innovative approach to pharmaceutical development, providing life-saving medicines to those in need. The Institute's entrepreneurial model combines pharmaceutical expertise with a social mission to address global health disparities.
The Institute for OneWorld Health is conducting a Phase III clinical trial to develop paromomycin as an affordable and cost-effective cure for visceral leishmaniasis. The trial, supported by the Bill & Melinda Gates Foundation, aims to provide an effective treatment for a disease that affects 1.5 million people worldwide.